Discovers and develops vaccine candidates to prevent serious infectious diseases. Utilizes proprietary recombinant nanoparticle technology for vaccine design. Now — the numbers.
The biggest line carries real weight, but it doesn’t decide everything on its own.
This is an established company with proven profits.
Average growth of 54% a year over the last 4 years. Red columns mark years that ended in a loss.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Profit indicators sit around the sector average.
Clearly below the class average.
The price isn’t cheap next to earnings — that’s why this grade sits in the middle.
Clearly above the class average — a step short of the very top.
The price is looking for direction — no strong breakout, no collapse.
Financial Strength: The cash-and-debt balance is thin; the buffer for hard times is slim.
An investor who bought at the very peak is down 96% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
The net profit margin is 39% — that slice of every sale is the company’s cushion in hard quarters.
Over the last 4 years, sales grew about 54% a year on average.
It met or beat analyst expectations in 7 of the last 8 quarters — consistency is a promise kept.
This stock swings about 2.5 times as much as the market average. Big rallies — and big drops — can both happen fast.
The balance sheet offers little cushion against a rough stretch. Report-card grade: 6/100.
Since the drop from its peak, buyer appetite hasn’t come back.
On our five-subject report card, NVAX sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: NVAX does earn real profits — but on our report card it still sits behind its class. The real debate isn’t the quality of the business — it’s what that quality should cost.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.
Analysts’ average target sits above today’s price, yet the valuation grade (56/100) says the stock isn’t cheap.